Contributions
Abstract: EP1360
Type: ePoster
Abstract Category: Clinical aspects of MS - 6 MS and gender
Background: Multiple sclerosis (MS) is a neurological disease mostly affecting women of childbearing age.
Recent studies suggest that MS may have a negative impact on fertility. In general, decreased ovarian reserve is supposed to be one of the most important factors for fertility impairment.
It is not known if ovarian decline contributes to accumulation of disability in women with MS when evaluated using the Expanded Disability Status Scale (EDSS). Anti-Mullerian hormone (AMH) is a peptide hormone that represents a simple and widely available measure of ovarian reserve unrelated to the menstrual cycle.
The purpose of this study was to determine AMH levels in females with relapsing-remitting MS (RRMS) in comparison with healthy volunteers.
Methods: A total of 104 reproductive-age females (mean age 33.3 ± 5,7) with RRMS and 107 age-matched healthy controls (HC, mean age 33.3 ± 5.6) were included in this case control study.
In females with MS, the median EDSS score was 2.5 points and the median disease duration was 5.1 years.
An enzymatically amplified two-site immunoassay was used to measure serum AMH level.
Results: On a group level, only an unsignificant trend to reduced AMH values was found in RRMS patients (2.91±2.4 ng/ml) in comparison to healthy controls (3.50±2.6 ng/ml) (p = 0.09).
However, when being analyzed in 6 separated age-related subgroups, significant reduction of AMH values was found in MS patients at the age of 35-40 (2.2 ± 1.4 ng/ml) compared to age-related healthy controls (3.8 ± 2.1 ng/ml) (p=0.01).
AMH values were not associated with EDSS in MS patients, but showed significant decrease with age both in healthy controls and MS group.
Conclusions: In general, no clear reduction in follicular reserve was found in MS women comparing to healthy controls. However, when being analyzed in particular age-related subgroups, the AMH values were lower MS patients than in HCs at the age of 35-40. These results suggest possible negative impact of MS disease on fertility particular at the age above 35, which should be considered in parenthood planning.
This study was supported by the Masaryk University Specific Research Grant, MUNI/A/1028/2016.
Disclosure: Srotova: nothing to disclose.
Svobodova: nothing to disclose.
Crha: nothing to disclose.
Kralickova Nekvapilova: nothing to disclose.
Valkovska: nothing to disclose.
Podborska: nothing to disclose.
Vlckova: nothing to disclose.
Stourac: nothing to disclose.
Bednarik: nothing to disclose.
Abstract: EP1360
Type: ePoster
Abstract Category: Clinical aspects of MS - 6 MS and gender
Background: Multiple sclerosis (MS) is a neurological disease mostly affecting women of childbearing age.
Recent studies suggest that MS may have a negative impact on fertility. In general, decreased ovarian reserve is supposed to be one of the most important factors for fertility impairment.
It is not known if ovarian decline contributes to accumulation of disability in women with MS when evaluated using the Expanded Disability Status Scale (EDSS). Anti-Mullerian hormone (AMH) is a peptide hormone that represents a simple and widely available measure of ovarian reserve unrelated to the menstrual cycle.
The purpose of this study was to determine AMH levels in females with relapsing-remitting MS (RRMS) in comparison with healthy volunteers.
Methods: A total of 104 reproductive-age females (mean age 33.3 ± 5,7) with RRMS and 107 age-matched healthy controls (HC, mean age 33.3 ± 5.6) were included in this case control study.
In females with MS, the median EDSS score was 2.5 points and the median disease duration was 5.1 years.
An enzymatically amplified two-site immunoassay was used to measure serum AMH level.
Results: On a group level, only an unsignificant trend to reduced AMH values was found in RRMS patients (2.91±2.4 ng/ml) in comparison to healthy controls (3.50±2.6 ng/ml) (p = 0.09).
However, when being analyzed in 6 separated age-related subgroups, significant reduction of AMH values was found in MS patients at the age of 35-40 (2.2 ± 1.4 ng/ml) compared to age-related healthy controls (3.8 ± 2.1 ng/ml) (p=0.01).
AMH values were not associated with EDSS in MS patients, but showed significant decrease with age both in healthy controls and MS group.
Conclusions: In general, no clear reduction in follicular reserve was found in MS women comparing to healthy controls. However, when being analyzed in particular age-related subgroups, the AMH values were lower MS patients than in HCs at the age of 35-40. These results suggest possible negative impact of MS disease on fertility particular at the age above 35, which should be considered in parenthood planning.
This study was supported by the Masaryk University Specific Research Grant, MUNI/A/1028/2016.
Disclosure: Srotova: nothing to disclose.
Svobodova: nothing to disclose.
Crha: nothing to disclose.
Kralickova Nekvapilova: nothing to disclose.
Valkovska: nothing to disclose.
Podborska: nothing to disclose.
Vlckova: nothing to disclose.
Stourac: nothing to disclose.
Bednarik: nothing to disclose.